Table 3.
Univariate and Multivariate Cox Regression of Factors Predicting Progression-Free Survival and Overall Survival.
| Variable | Progression-Free Survival | Overall Survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95% CI) |
p Value | HR (95% CI) |
p Value | HR (95% CI) |
p Value | HR (95% CI) |
p Value | |
| Age | 0.98 (0.96–0.99) |
0.009 | NS | - | NS | - | NS | - |
| Stage IV at diagnosis | 2.03 (1.47–2.81) |
<0.001 | NS | - | 1.62 (1.14–2.30) |
0.007 | NS | - |
| Nodal involvement at baseline (N+) | 1.70 (1.24–2.33) |
0.001 | NS | - | 1.71 (1.20–2.45) |
0.003 | 1.6 (1.1–2.4) |
0.049 |
| No response after primary treatment |
2.04 (1.25–3.34) |
0.005 | NS | - | NS | - | NS | - |
| ECOG PS = 1 | 1.75 (1.27–2.41) |
0.001 | 1.9 (1.3–2.6) |
<0.001 | 2.06 (1.46–2.92) |
<0.001 | 1.7 (1.1–2.6) |
0.011 |
| Type of oligometastatic disease | 1.21 (1.07–1.37) |
0.002 | NS | - | NS | - | NS | - |
| No. of lesions at OMD diagnosis |
1.27 (1.09–1.48) |
0.003 | NS | - | 1.29 (1.07–1.55) |
0.007 | NS | - |
| Primary tumor uncontrolled |
1.78 (1.24–2.55) |
0.002 | NS | - | 1.65 (1.11–2.44) |
0.013 | NS | - |
| Intracranial metastatic disease | 2.78 (2.00–3.83) |
<0.001 | 2.4 (1.7–3.4) |
<0.001 | 2.79 (1.90–4.10) |
<0.001 | 2.3 (1.4–3.9) |
0.001 |
| CMT for OMD | 2.5 (1.7–3.5) |
<0.001 | 1.9 (1.3–2.6) |
0.002 | 1.77 (1.21–2.57) |
0.003 | 1.7 (1.1–2.6) |
0.020 |
| No response after LAT | 4.36 (2.27–8.38) |
<0.001 | 4.4 (2.2–8.5) |
<0.001 | NS | - | NS | - |
| New local treatment for PD | NS | - | NS | - | 2.01 (1.35–3.00) |
0.001 | NS | - |
| No local treatment for PD vs. Intracranial vs. Extracranial new site of local treatment | NA | - | NA | - | 1.85 (1.41–2.43) |
<0.001 | 2.2 (1.6–3.1) |
<0.001 |
ECOG = Eastern Cooperative Oncology Group, PS = Performance Status, OMD = oligometastatic disease, CMT = chemotherapy in combination with LAT, LAT = local ablative therapy (SABR/SRS), PD = progression disease, NS = not significant, NA = not available.